EHMTI-0223. Botox in the prevention of chronic migraine; 18-months follow up outcome in 67 patients
- 494 Downloads
KeywordsPublic Health Internal Medicine Migraine Adult Patient Large Cohort
Chronic migraine (CM) affects 2% of the population and Botox is the only licensed treatment for prevention of adult patients with CM.
In the UK, National Institute for Clinical Excellence (NICE) approved its use on the NHS in patients who failed three preventive medications.
NICE recommends continuing treatment beyond cycle 2 in those with 30% reduction in headache days (negative stopping rule) and the treatment is stopped when migraine become episodic (positive stopping rule).
However, the long-term outcome ie duration of required treatment remains uncertain.
To ascertain the duration of treatment with Botox for the prevention of chronic migraine in responders as per NICE criteria.
Adult patients with CM attending the Hull migraine clinic were offered Botox based on clinical needs and maintained a headache diary.
Data were extracted for headache, migraine, and headache-free days
Responder rate was assessed applying NICE criteria
Patients (N=67) who commenced treatment between July 2010 and June 2012 were followed up for at least 18 months.
30 Patients stopped treatment at Cycle 2 as per negative stopping rule by NICE
Of 37 responders, only 12 were still on treatment at 18 months. Nearly half of the patients stopped treatment by the 4th Cycle (positive stopping rule).
We continue to follow all patients who receive Botox for prevention of chronic migraine and aim to present 2 year follow up on a larger cohort at the EHMTIC September 2014.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.